research highlights from the national institute of diabetes and digestive and kidney diseases...
Post on 22-Dec-2015
213 Views
Preview:
TRANSCRIPT
Research Highlights from the Research Highlights from the National Institute of Diabetes and National Institute of Diabetes and
Digestive and Kidney DiseasesDigestive and Kidney Diseases
Griffin P. Rodgers, M.D., M.A.C.P.Griffin P. Rodgers, M.D., M.A.C.P.
Acting DirectorActing Director
National Institute of Diabetes and National Institute of Diabetes and Digestive and Kidney DiseasesDigestive and Kidney Diseases
Diabetes, Endocrinology, and Diabetes, Endocrinology, and Metabolic Diseases;Metabolic Diseases;
Digestive Diseases and Nutrition; andDigestive Diseases and Nutrition; and
Kidney, Urologic, and Hematologic Kidney, Urologic, and Hematologic Diseases.Diseases.
The NIDDK conducts and supports The NIDDK conducts and supports basic and applied research and basic and applied research and provides leadership for a national provides leadership for a national program in:program in:
NIDDK’s Research and NIDDK’s Research and Dissemination SpectrumDissemination Spectrum
““Bench to Bedside and Beyond”Bench to Bedside and Beyond”
Organizational Structure of Organizational Structure of NIDDK’s Three Extramural NIDDK’s Three Extramural
Scientific DivisionsScientific Divisions
NIDDKNIDDK
KUHKUHDivision of Kidney,Division of Kidney,
Urologic, andUrologic, andHematologicHematologic
Diseases Diseases
DDNDDNDivision ofDivision of
Digestive DiseasesDigestive Diseasesandand
Nutrition Nutrition
DEDEMMDivision of Division of Diabetes, Diabetes,
Endocrinology, Endocrinology, and and
Metabolic Metabolic Diseases Diseases
A Paradigm of NIDDK’s Integrated A Paradigm of NIDDK’s Integrated Research ProgramsResearch Programs
ObesityObesityType 2Type 2
DiabetesDiabetesKidneyKidney
DiseaseDisease
Overweight and ObesityOverweight and Obesity
BMI below 18.5 – UnderweightBMI below 18.5 – Underweight
BMI between 18.5 and 24.9 – Healthy weightBMI between 18.5 and 24.9 – Healthy weight
BMI between 25 and 29.9 – OverweightBMI between 25 and 29.9 – Overweight
BMI 30 and above – ObeseBMI 30 and above – Obese
BMI below 5th percentile – UnderweightBMI below 5th percentile – Underweight
BMI between 5th and less than 85th – Healthy BMI between 5th and less than 85th – Healthy weightweight
BMI between 85th and less than 95th – At BMI between 85th and less than 95th – At Risk of OverweightRisk of Overweight
BMI 95th percentile and above – OverweightBMI 95th percentile and above – Overweight
For AdultsFor Adults
For Children and AdolescentsFor Children and Adolescents
PhlebitisPhlebitisvenous venous stasisstasis
Coronary heart Coronary heart diseasedisease
Pulmonary diseasePulmonary diseaseabnormal functionabnormal functionobstructive sleep apneaobstructive sleep apneahypoventilation syndromehypoventilation syndrome
Gall bladder Gall bladder diseasedisease
GoutGout
DiabetesDiabetes
OsteoarthritisOsteoarthritis
Nonalcoholic fatty liver Nonalcoholic fatty liver diseasediseasesteatosissteatosissteatohepatitissteatohepatitiscirrhosiscirrhosis
HypertensionHypertensionDyslipidemiaDyslipidemia
CataractsCataracts
SkinSkin
PancreatitisPancreatitis
CancerCancerbreast, uterus, cervix, prostate, kidneybreast, uterus, cervix, prostate, kidneycolon, esophagus, pancreas, livercolon, esophagus, pancreas, liver
Gynecologic abnormalitiesGynecologic abnormalitiesabnormal mensesabnormal mensesinfertilityinfertilitypolycystic ovarian syndromepolycystic ovarian syndrome
StrokeStroke
Health Complications of ObesityHealth Complications of ObesityIdiopathic intracranial Idiopathic intracranial
hypertensionhypertension
00
55
1010
1515
2020
00
55
1010
1515
2020
Perc
en
tPerc
en
t
Perc
en
tPerc
en
t6-11 years old6-11 years old
12-19 years old12-19 years old
Trends in U.S. Child and Trends in U.S. Child and Adolescent OverweightAdolescent Overweight
1963
-196
7
1963
-196
7
1999
-200
0
1999
-200
0
2001
-200
2
2001
-200
2
2003
-200
4
2003
-200
4
1971
-197
4
1971
-197
4
1976
-198
0
1976
-198
0
1988
-199
4
1988
-199
4
Obesity: Gene/Environment Obesity: Gene/Environment InteractionsInteractions
Current environment
Past environment
Genetic susceptibility
Ad
ipoci
ty p
hen
oty
pe
(e.g
., b
od
y m
ass
in
dex)
ObesityObesityType 2Type 2
DiabetesDiabetesKidneyKidney
DiseaseDisease
A Paradigm of NIDDK’s A Paradigm of NIDDK’s Integrated Research ProgramsIntegrated Research Programs
Two Major Forms of DiabetesTwo Major Forms of Diabetes
Usually diagnosed in childhood, adolescence, or young Usually diagnosed in childhood, adolescence, or young adulthoodadulthood
Body’s immune defense system mistakenly destroys Body’s immune defense system mistakenly destroys insulin-producing cells in the pancreas (autoimmunity) insulin-producing cells in the pancreas (autoimmunity)
Results in lack of insulin to control blood sugar levels; Results in lack of insulin to control blood sugar levels; insulin therapy lifesaving but not a cureinsulin therapy lifesaving but not a cure
Historically diagnosed in adults; now in children and Historically diagnosed in adults; now in children and adolescentsadolescents
Body has reduced sensitivity to insulinBody has reduced sensitivity to insulin
Therapy increases insulin release/sensitivity; some insulin Therapy increases insulin release/sensitivity; some insulin administration may be requiredadministration may be required
Obesity is a serious risk factorObesity is a serious risk factor
Can be prevented or delayed by diet and exercise as Can be prevented or delayed by diet and exercise as shown in NIH clinical trialsshown in NIH clinical trials
Type 1Type 1
Type 2Type 2
No Data <4% 4-4.9% 5-5.9% ≥6%
19941994 20042004
Estimates of Diagnosed Diabetes Among Adults in the U.S.
Diabetes: Burden of DiseaseDiabetes: Burden of Disease
20.8 million 20.8 million AmericansAmericans ((7 percent 7 percent of the of the
U.S. population) have diabetesU.S. population) have diabetes
90-9590-95 percent of cases are type 2 percent of cases are type 2
diabetesdiabetes
Minorities Minorities are disproportionately affected are disproportionately affected
by type 2 diabetesby type 2 diabetes
1 in 31 in 3 Americans born in 2000 is predicted Americans born in 2000 is predicted
to develop diabetes during his or her to develop diabetes during his or her
lifetime (for Hispanic females: lifetime (for Hispanic females: 1 in 21 in 2))
0
10
20
30
40
50
1960
1970
1970
1980
1980
1990
1990
2000
2000
2010
2010
2020
2020
2030
2030
2040
2040
2050
2050
Peop
le (
million
s)
Peop
le (
million
s)
YearYear
Diagnosed Diabetes in the U.S. Diagnosed Diabetes in the U.S. Diagnosed (1960-2004) Diagnosed (1960-2004) and and
Projected Diagnosed (2005-2050)Projected Diagnosed (2005-2050) Cases Cases
Diagnosed casesDiagnosed casesProjected Projected
diagnosed casesdiagnosed cases
Results from the Diabetes Prevention Program Results from the Diabetes Prevention Program Substantial Reduction in DiabetesSubstantial Reduction in Diabetes
in All Race-Ethnic Groupsin All Race-Ethnic Groups
LifestyleLifestyle MetforminMetformin Placebo/Standard carePlacebo/Standard care
Case
s per
100 p
ers
on-y
ears
Case
s per
100 p
ers
on-y
ears
00
33
66
99
1212
1515
All participantsAll participants CaucasianCaucasian AfricanAfricanAmericanAmerican
HispanicHispanic AmericanAmericanIndianIndian
AsianAsian
Complications Common to Both Complications Common to Both Type 1 and Type 2 DiabetesType 1 and Type 2 Diabetes
Blindness
Kidney Kidney DiseaseDisease
Stroke
Heart Disease
AtherosclerosisAtherosclerosis
Foot Ulcers and Amputations
Acute complicationsAcute complications
Chronic complicationsChronic complications
Dangerously high or low Dangerously high or low blood glucoseblood glucose
→ → ccoma, death oma, death
Affect all major organsAffect all major organs
Develop over time/ Develop over time/ exposure to high blood exposure to high blood glucoseglucose
Tight control of blood Tight control of blood glucose can prevent or glucose can prevent or delaydelay
ObesityObesityType 2Type 2
DiabetesDiabetesKidneyKidney
DiseaseDisease
A Paradigm of NIDDK’s A Paradigm of NIDDK’s Integrated Research ProgramsIntegrated Research Programs
End-stage Renal Disease in the U.S. End-stage Renal Disease in the U.S. Number of Patients per Million PopulationNumber of Patients per Million Population
19931993 20032003
End-stage Renal Disease in the U.S.End-stage Renal Disease in the U.S.All Values are for Calendar Year 2004All Values are for Calendar Year 2004
Prevalence: Prevalence: 472,099472,099 patients were patients were undergoing treatmentundergoing treatment
Mortality: Mortality: 84,25284,252 deaths in patients deaths in patients undergoing treatment for ESRDundergoing treatment for ESRD
Primary cause:Primary cause:
Diabetes: Diabetes: 45,87145,871
High blood pressure: High blood pressure: 28,13228,132
Primary treatment:Primary treatment:
Dialysis: Dialysis: 335,963335,963 patients received dialysis patients received dialysis
Kidney Transplant: Kidney Transplant: 16,90516,905 performed performed
Minorities Minorities are disproportionately affectedare disproportionately affected
End-stage Renal Disease in the U.S. End-stage Renal Disease in the U.S. Adjusted Incident Rates & Annual Percent ChangeAdjusted Incident Rates & Annual Percent Change
Progress in Combating the Progress in Combating the U.S. ESRD EpidemicU.S. ESRD Epidemic
After 20 years of annual increases from 5 to 10 After 20 years of annual increases from 5 to 10 percent, rates for new cases of kidney failure percent, rates for new cases of kidney failure have stabilizedhave stabilized
Better disease prevention methods appear to Better disease prevention methods appear to be responsiblebe responsible
Use of angiotensin-converting enzyme inhibitors Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and angiotensin receptor blockers
Better glycemic controlBetter glycemic control
Better blood pressure control Better blood pressure control
NIH research has established the value of these NIH research has established the value of these interventionsinterventions
But, progress has not yet been realized across all But, progress has not yet been realized across all U.S. populationsU.S. populations
Incident Diabetic End-stage Incident Diabetic End-stage Renal Disease in the U.S.Renal Disease in the U.S.
Age 20 to 29 YearsAge 20 to 29 Years
00
55
1010
1515
2020
2525
3030
3535
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
YearYear
Per
mill
ion
pop
ula
tion
Per
mill
ion
pop
ula
tion CaucasianCaucasian
African AmericanAfrican American
More Insights into Preventing More Insights into Preventing Complications of DiabetesComplications of Diabetes
Microvascular damage – retinopathy
Macrovascular damage – CVD
Preventing complications by preventing diabetes - DPP
Eye Disease: Intensive Diabetes Eye Disease: Intensive Diabetes Treatment Reduces RiskTreatment Reduces Risk
00
2525
5050
7575
100100
Study YearsStudy Years
00 11 22 33 44 55 66 77 88 99
Cum
ulat
ive
Per
cent
Cum
ulat
ive
Per
cent
ConventionalConventional
Cumulative Incidence Cumulative Incidence of of >> 3-Step Change 3-Step Change
p = 0.001p = 0.001
IntensiveIntensive
Cum
ulat
ive
Inci
denc
e of
Non
fata
lC
umul
ativ
e In
cide
nce
of N
onfa
tal
Myo
card
ial I
nfar
ctio
n, S
trok
e, o
r M
yoca
rdia
l Inf
arct
ion,
Str
oke,
or
Dea
th f
rom
Car
diov
ascu
lar
Dis
ease
Dea
th f
rom
Car
diov
ascu
lar
Dis
ease
0.000.00
0.020.02
0.040.04
0.060.06
Years Since Entry into DCCT/EDIC StudyYears Since Entry into DCCT/EDIC Study
ConventionalConventional
IntensiveIntensive
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 210 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Heart Disease: Heart Disease: Intensive Diabetes Intensive Diabetes Treatment Reduces RiskTreatment Reduces Risk
Strategic Plan for NIH Obesity ResearchStrategic Plan for NIH Obesity Research
Research Toward Preventing and Research Toward Preventing and Treating Obesity Through Behavioral Treating Obesity Through Behavioral and Environmental Approaches to and Environmental Approaches to Modify Lifestyle, with an Emphasis on Modify Lifestyle, with an Emphasis on Childhood ObesityChildhood Obesity
Research Toward Preventing and Research Toward Preventing and Treating Obesity Through Treating Obesity Through Pharmacologic, Surgical, or Other Pharmacologic, Surgical, or Other Medical ApproachesMedical Approaches
Research Toward Understanding the Research Toward Understanding the Relationship Between Obesity and Its Relationship Between Obesity and Its Associated Health ConditionsAssociated Health Conditions
Cross-cutting Topics – Technology, Cross-cutting Topics – Technology, Multidisciplinary/Interdisciplinary Multidisciplinary/Interdisciplinary Research Teams, Translational Research Teams, Translational Research, Training, Research, Training, Education/OutreachEducation/Outreach
Developed by the NIH Obesity Research Task Force with Developed by the NIH Obesity Research Task Force with critical input from external scientists and the publiccritical input from external scientists and the public
Although listed separately, the first two themes are interdependent. We seek to create an interdisciplinary approach in which lifestyle interventions are informed by an understanding of the basic biological and genetic factors and vice versa.
Conquering Diabetes: A Scientific Conquering Diabetes: A Scientific Progress Report on Progress Report on The Diabetes Research The Diabetes Research
Working Group’sWorking Group’s Strategic Plan Strategic Plan
GeneticsGenetics
Autoimmunity and the Autoimmunity and the Beta CellBeta Cell
Cell Signaling and Cell Cell Signaling and Cell RegulationRegulation
ObesityObesity
Clinical Research and Clinical Research and Clinical Trials of Critical Clinical Trials of Critical ImportanceImportance
Highlights of Program Efforts, Highlights of Program Efforts, Research Advances and Research Advances and Opportunities related to:Opportunities related to:
Progress and Priorities: Progress and Priorities: Renal Disease Research PlanRenal Disease Research Plan
Important scientific Important scientific resources needed to resources needed to reach research goals reach research goals include:include:Conducting More Conducting More Epidemiological StudiesEpidemiological Studies
Creating Centers and Creating Centers and CooperativesCooperatives
Creating New Ways to Study Creating New Ways to Study Renal InjuryRenal Injury
Focusing More on Genetic Focusing More on Genetic SusceptibilitySusceptibility
Developing a Renal Genomics Developing a Renal Genomics ProjectProject
Increasing Research on Increasing Research on TreatmentsTreatments
Examples of NIH and NIDDK Examples of NIH and NIDDK Education and Outreach ProgramsEducation and Outreach Programs
The The Weight-control Information NetworkWeight-control Information Network (WIN) is an information service of the NIDDK. (WIN) is an information service of the NIDDK. WIN was established in 1994 to provide the WIN was established in 1994 to provide the general public, health professionals, the general public, health professionals, the media, and Congress with up-to-date, media, and Congress with up-to-date, science-based information on obesity, weight science-based information on obesity, weight control, physical activity, and related control, physical activity, and related nutritional issues. nutritional issues.
WIN produces, collects, and disseminates WIN produces, collects, and disseminates materials on obesity, weight control, and materials on obesity, weight control, and nutrition.nutrition.
Weight-control Weight-control Information NetworkInformation Network
National Diabetes National Diabetes Education ProgramEducation Program
The The National Diabetes Education National Diabetes Education ProgramProgram (NDEP) is a federally (NDEP) is a federally funded program sponsored by the funded program sponsored by the National Institutes of Health and National Institutes of Health and the Centers for Disease Control and the Centers for Disease Control and Prevention and includes over 200 Prevention and includes over 200 partners at the federal, state, and partners at the federal, state, and local levels, working together to local levels, working together to reduce the morbidity and mortality reduce the morbidity and mortality associated with diabetes.associated with diabetes.
Components of the National Components of the National Diabetes Education ProgramDiabetes Education ProgramControl Your Diabetes. For Life.Control Your Diabetes. For Life. - To promote - To promote the importance and benefits of diabetes controlthe importance and benefits of diabetes controlBe Smart About Your Heart. Control the ABCs of Be Smart About Your Heart. Control the ABCs of DiabetesDiabetes - Encourages control of blood sugar, - Encourages control of blood sugar, blood pressure, and cholesterolblood pressure, and cholesterolSmall Steps. Big Rewards. Prevent type 2 Small Steps. Big Rewards. Prevent type 2 DiabetesDiabetes - Translate and promote the Diabetes - Translate and promote the Diabetes Prevention Program (DPP) clinical trial findingsPrevention Program (DPP) clinical trial findings
National Kidney DiseaseNational Kidney DiseaseEducation ProgramEducation Program
NKDEP
The The National Kidney Disease National Kidney Disease Education ProgramEducation Program (NKDEP) is an (NKDEP) is an initiative of the National Institutes of initiative of the National Institutes of Health, designed to reduce the Health, designed to reduce the morbidity and mortality caused by morbidity and mortality caused by kidney disease and its complications.kidney disease and its complications.
top related